Publicar

SCHISTOSOMA MANSONI E O DESENVOLVIMENTO DE RESISTÊNCIA FRENTE AO TRATAMENTO COM PRAZIQUANTEL: UM RESUMO DA LITERATURA

Doi: 10.47094/XXXSBM.2025/13

PALAVRAS CHAVE: Esquistossomose. Fármaco. Tolerância.

KEYWORDS: Schistosomiasis. Drug. Tolerance.

ABSTRACT:
Introduction: Schistosomiasis, caused by the trematode Schistosoma mansoni, is considered a neglected tropical disease, affecting approximately 250 million people in more than 55 countries, mainly in Africa and the Americas, especially in Brazil. It affects mostly socioeconomically vulnerable individuals. Furthermore, there is no vaccine and only the drug praziquantel (PZQ) is used in its treatment regimen. However, only 20% of those infected receive treatment for the disease[5]. Furthermore, there is evidence in the literature of parasite strains developing resistance to the only drug available for over 50 years[2][4]. Objective: This study aims to review the literature and highlight the need for research into new drug options for schistosomiasis.

Autores

  • André de Lima Aires

  • Arthur Lessa Machado

  • Beatriz Estandislau Lins de Carvalho

  • Maiara Eduarda de Souza Pereira

  • Matheus Campos de Andrade

Download